ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results
The RP2D of ACR-368 with irinotecan by age group is ACR-368 105 or 150 mg/m<sup>2</sup> once on day 1 (>21 years or ≤21 years, respectively) and irinotecan 15 mg/m<sup>2</sup> once daily for 5 days in 21-day cycles for both groups. The study met its primary objective to consider ACR-368 and irinotecan promising in DSRCT and, to our knowledge, is the first incorporating a targeted therapy to achieve this magnitude of response.
Authors
- Emily K. Slotkin (ORCID: https://orcid.org/0000-0002-4463-5759)
- Anita P. Price (ORCID: https://orcid.org/0000-0002-3917-6666)
- Michael D. Kinnaman (ORCID: https://orcid.org/0000-0001-6448-1569)
- Caroline M. Robb (ORCID: https://orcid.org/0000-0002-9126-1307)
- Gerald Behr (ORCID: https://orcid.org/0000-0002-2987-0005)
- Viswatej Avutu (ORCID: https://orcid.org/0000-0002-2591-7187)
- Neeta D. Pandit-Taskar (ORCID: https://orcid.org/0000-0003-1551-2036)
- Paul A. Meyers (ORCID: https://orcid.org/0000-0001-6146-6101)
- Ping Chi
- Sagarika Pachhal
- Audrey Mauguen (ORCID: https://orcid.org/0000-0003-3236-6093)
- Sinchun Hwang (ORCID: https://orcid.org/0000-0002-6402-3020)
- Damon R. Reed (ORCID: https://orcid.org/0000-0002-8238-2465)
- Romel Somwar
- William D. Tap (ORCID: https://orcid.org/0000-0001-7779-2796)
- Katherine A. Thornton
- Mrinal M. Gounder (ORCID: https://orcid.org/0000-0001-8468-0119)
- Tara J. O’Donohue (ORCID: https://orcid.org/0000-0001-9814-0690)
- Mark A. Dickson (ORCID: https://orcid.org/0000-0003-2764-751X)
- Marc Ladanyi (ORCID: https://orcid.org/0000-0001-9055-7213)
- Benjamin A. Nacev (ORCID: https://orcid.org/0000-0003-4991-2492)
- Evan Rosenbaum (ORCID: https://orcid.org/0000-0002-7499-1279)
- Alex Kentsis (ORCID: https://orcid.org/0000-0002-8063-9191)
- Andrew L. Kung (ORCID: https://orcid.org/0000-0002-9091-488X)
- Filemon S. Dela Cruz (ORCID: https://orcid.org/0000-0002-8356-5191)
- Ciara M. Kelly (ORCID: https://orcid.org/0000-0002-4393-8088)
- Leonard H. Wexler (ORCID: https://orcid.org/0000-0003-0724-8263)
- Michael Vincent Ortiz (ORCID: https://orcid.org/0000-0001-9379-314X)
- Julia Glade Bender (ORCID: https://orcid.org/0000-0001-5316-6440)
- Sandra P. D’Angelo (ORCID: https://orcid.org/0000-0002-3736-3783)
- Mary Lou Keohan
Institutions
- Memorial Sloan Kettering Cancer Center (US)
Publication Details
- Journal
- JCO oncology advances.
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1200/oa-24-00095
- Citations
- 2
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04